hi eire, what did you mean by ‘.... or moved out of what we know...

hi eire, what did you mean by ‘.... or moved out of what we know ...’ bit mate?, infusions exit was a given as per AI.

guess the only thing Admedus ‘knew’ was to focus on IP related solely to the Cardiovascular field and we ‘are’ still doing it?, yes?

would you agree or not that a TAVR deal is absolutely needed and would be a immediate catalyst to turn around this company, what else is there in the immediate future (next six months) that will enable the further expansion of future products before funding situation becomes a problem again.

what the future will look like, imo, regardless of perhaps the irrelevance of the next quarterly (?) is future outgoings, half of the current windfall will be spent soon enough thus our wagon may well and truly be hitched to the TAVR wagon.

if future sales figures do trigger of future revenue as per term agreements you would have to absolutely wonder what Admedus was doing (not) prior, from double to four fold is staggering, doable or not?, yes, absolutely, ‘but’ will it be when it counts the most ....year one and two.